Key facts
- This page summarizes Sean E. Browne's Form 4 filing for Xtant Medical Holdings, Inc. (XTNT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Oct 2022, 16:19.
Sean E. Browne - 18 Oct 2022 Form 4 Insider Report for Xtant Medical Holdings, Inc. (XTNT)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- XTNT
- Reported as of
- 18 Oct 2022
- Net transaction value
- -$85,828
- SEC form
- 4
- Accepted by SEC
- 20 Oct 2022, 16:19:49 UTC
- Prior SEC filing
- 18 Oct 2021
- Next SEC filing
- 17 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Amy Culbert, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Sean E. Browne filed Form 4 for Xtant Medical Holdings, Inc. (XTNT) on 20 Oct 2022.
Change
- Previous filing in this sequence was filed on 18 Oct 2021.
- Current net transaction value: -$85,828.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XTNT
transaction
Common Stock, $0.000001 par value
Sale
- Transaction value
- $54,008
- Shares
- -80,000
- Change %
- -4.9%
- Price
- $0.6751
- Shares after
- 1,557,684
- Date
- 18 Oct 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3
XTNT
transaction
Common Stock, $0.000001 par value
Sale
- Transaction value
- $31,820
- Shares
- -51,100
- Change %
- -3.3%
- Price
- $0.6227
- Shares after
- 1,506,584
- Date
- 19 Oct 2022
- Ownership
- Direct
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6461 to $0.79, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Footnote F3
Includes 131,618 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan and 734,430 shares that will be issued over time subject to vesting pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6017 to $0.6433, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.